OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Johnson on the Need for Novel Biomarkers in Melanoma

September 15th 2020

Douglas B. Johnson, MD, MSCI, discusses the need to identify novel biomarkers in melanoma.

Dr. McGregor on Future Research in mCRPC

September 15th 2020

Bradley McGregor, MD, discusses future research in metastatic castration-resistant prostate cancer.

Dr. Pal on the Rationale for the TIVO-3 Trial With Tivozanib in Advanced RCC

September 15th 2020

Sumanta K. Pal, MD, discusses the rationale behind the phase 3 TIVO-3 trial with tivozanib in advanced renal cell carcinoma.

Dr. Motzer on the TIVO-1 Trial With Tivozanib in Advanced RCC

September 15th 2020

Robert J. Motzer, MD, discusses the phase 3 TIVO-1 trial comparing tivozanib with sorafenib in patients with advanced renal cell carcinoma.

Dr. VanderWalde on the Importance of Multidisciplinary Care in Rectal Cancer

September 15th 2020

Noam VanderWalde, MD, MS, discusses the importance of implementing multidisciplinary care for patients with rectal cancer.

Dr. Visco on the Utility of Bendamustine in MCL

September 15th 2020

Carlo Visco, MD, discusses the utility of bendamustine-based regimens in mantle cell lymphoma.

Dr. Vaishampayan on the Safety of Tivozanib Versus Sorafenib in RCC

September 15th 2020

Ulka N. Vaishampayan, MBBS, FAB, discusses the safety of tivozanib versus sorafenib in advanced renal cell carcinoma.

Dr. Woyach on Clinical Trials Examining Novel Triplets in CLL

September 14th 2020

Jennifer Woyach, MD, discusses clinical trials examining novel triplet regimens in chronic lymphocytic leukemia.

Dr. Maddocks on the Role of Tazemetostat in EZH2-Mutant Follicular Lymphoma

September 14th 2020

Kami J. Maddocks, MD, discusses the role of tazemetostat in patients with EZH2-mutant follicular lymphoma.

Dr. Choudhury on Clinical Trials of Interest in Nonmetastatic CRPC

September 14th 2020

Atish D. Choudhury, MD, PhD, discusses clinical trials of interest examining different agents, such as darolutamide, enzalutamide, and apalutamide in patients with nonmetastatic castration-resistant prostate cancer.

Dr. Spivak on the Prevalence of Polycythemia Vera

September 14th 2020

Jerry Le Pow Spivak, MD, discusses the prevalence of polycythemia vera.

Dr. Leslie on the Role of Zanubrutinib in MCL

September 14th 2020

Lori A. Leslie, MD, discusses the role of zanubrutinib in mantle cell lymphoma.

Dr. Ghosh on Approved BTK Inhibitors in B-Cell Malignancies

September 14th 2020

Nilanjan Ghosh, MD, PhD, discusses approved BTK inhibitors in B-cell malignancies.

Dr. Kim on the Safety Profile of Atezolizumab/Bevacizumab in HCC

September 14th 2020

Richard D. Kim, MD, discusses the safety profile of the combination of atezolizumab and bevacizumab in hepatocellular carcinoma.

Dr. Grothey on Choosing Between Regorafenib and TAS-102 in mCRC

September 14th 2020

Axel Grothey, MD, discusses factors to consider when selecting between regorafenib and trifluridine/tipiracil in metastatic colorectal cancer.

Dr. Costa on the Promising Role of CAR T-Cell Therapy in Multiple Myeloma

September 14th 2020

Luciano J. Costa, MD, PhD, discusses the promising role of CAR T-cell therapy in relapsed/refractory multiple myeloma.

Dr. Woyach on the Safety of Acalabrutinib Versus Ibrutinib in CLL

September 11th 2020

Jennifer Woyach, MD, discusses the safety profile of acalabrutinib compared with ibrutinib in chronic lymphocytic leukemia.

Dr. Han on the APHINITY Trial in HER2+ Early-Stage Breast Cancer

September 11th 2020

Heather S. Han, MD, discusses the benefit of adding pertuzumab to trastuzumab and chemotherapy in the phase 3 APHINITY trial in patients with HER2-positive early-stage breast cancer.

Dr. Pautier on Remaining Challenges in Advanced Soft Tissue Sarcoma

September 11th 2020

Patricia Pautier, MD, discusses remaining challenges in treating patients with metastatic/advanced uterine and soft tissue leiomyosarcoma.

Dr. Arora on the Evolving Treatment Landscape in Multiple Myeloma

September 11th 2020

Shagun Arora, MD, discusses the rapidly advancing multiple myeloma treatment landscape.